Prohost Letter #452
Treating Untreatable Disease - NASH
Non Alcoholic Steatohepatitis
The efforts spent on treating Non Alcoholic Steatohepatitis (NASH) have reached a promising stage where clinical trial data from the clinical-stage and revenue-generating biotech firms have demonstrated capability of treat NASH. The most promising of these firms we believe, are clinical-stage firms, especially those firms that have already demonstrated capability of regressing fibrosis in NASH patients.
The advancement in Non Alcoholic Steatohepatitis treatment is unprecedented.
Treating NASH has been an extremely difficult task for the biotechnology and biopharma firms.
No product has yet to be approved.
The . . .
This content is for paid subscribers.
Prohost Letters October 13, 2022